Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 5Phase 1 4Phase 1/2 2Phase 4 1

Status

Active not recruiting 3Recruiting 2Completed 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

NET 6Gastrointestinal 6Endocrine 6Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 291Prostatic Neoplasms 195Neoplasm Metastasis 155Multiple Myeloma 148Colorectal Neoplasms 124Lung Neoplasms 105Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 89Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 81Stomach Neoplasms 76Small Cell Lung Carcinoma 73Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 67Pain 66Carcinoma, Renal Cell 65Uterine Cervical Neoplasms 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

pasireotide 2Octreotide 2Everolimus 2lutetium Lu 177 dotatate 1lanreotide 1amino-acid, glucose, and electrolyte solution 1Temozolomide 1Sunitinib 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Oxaliplatin 1Leucovorin 1Folfox protocol 1Fluorouracil 1Capecitabine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Gastro-enteropancreatic neuroendocrine tumor × Clear all
NCT06784752 2026-04-30

NETTER-3

Novartis

Phase 3 Recruiting
240 enrolled
EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT05050942 2025-11-06

SORENTO

Camurus AB

Phase 3 Active not recruiting
332 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04919226 2025-09-10

COMPOSE

ITM Solucin GmbH

Phase 3 Active not recruiting
259 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04852679 2024-10-01

PALACE

Ipsen

Phase 3 Completed
43 enrolled 16 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡